CA2144409A1 - Peptides induisant une tolerance chez les cellules t et compositions a base de ces peptides - Google Patents

Peptides induisant une tolerance chez les cellules t et compositions a base de ces peptides

Info

Publication number: CA2144409A1
Authority: CA; Canada
Prior art keywords: antigen; cells; individual; peptide; tolerizing
Prior art date: 1992-09-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002144409A

Other languages

English (en)

Inventor

Paul M. Allen

Joanne Sloan-Lancaster

Brian D. Evavold

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Washington University School of Medicine

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-09-11

Filing date

1993-09-09

Publication date

1994-03-31

1993-09-09 Application filed by Individual filed Critical Individual

1994-03-31 Publication of CA2144409A1 publication Critical patent/CA2144409A1/fr

Status Abandoned legal-status Critical Current

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 192
210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 114
239000000203 mixture Substances 0.000 title claims abstract description 57
102000004196 processed proteins & peptides Human genes 0.000 title claims description 43
239000000427 antigen Substances 0.000 claims abstract description 126
108091007433 antigens Proteins 0.000 claims abstract description 126
102000036639 antigens Human genes 0.000 claims abstract description 126
210000000612 antigen-presenting cell Anatomy 0.000 claims abstract description 46
230000001225 therapeutic effect Effects 0.000 claims abstract description 43
230000002163 immunogen Effects 0.000 claims abstract description 30
230000035755 proliferation Effects 0.000 claims abstract description 26
108091008874 T cell receptors Proteins 0.000 claims abstract description 24
102000016266 T-Cell Antigen Receptors Human genes 0.000 claims abstract description 24
238000000034 method Methods 0.000 claims abstract description 16
230000035945 sensitivity Effects 0.000 claims abstract description 11
238000002054 transplantation Methods 0.000 claims abstract description 10
239000013566 allergen Substances 0.000 claims abstract description 7
238000001727 in vivo Methods 0.000 claims abstract description 4
238000004519 manufacturing process Methods 0.000 claims description 25
108010002350 Interleukin-2 Proteins 0.000 claims description 19
238000000099 in vitro assay Methods 0.000 claims description 15
150000001413 amino acids Chemical class 0.000 claims description 13
108010002386 Interleukin-3 Proteins 0.000 claims description 12
201000010099 disease Diseases 0.000 claims description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
208000024891 symptom Diseases 0.000 claims description 7
125000003275 alpha amino acid group Chemical group 0.000 claims description 6
239000003085 diluting agent Substances 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 6
238000006467 substitution reaction Methods 0.000 claims description 6
150000001875 compounds Chemical class 0.000 claims description 5
206010052779 Transplant rejections Diseases 0.000 claims description 3
108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 2
125000000539 amino acid group Chemical group 0.000 claims description 2
210000000987 immune system Anatomy 0.000 claims description 2
230000002401 inhibitory effect Effects 0.000 claims description 2
239000003814 drug Substances 0.000 claims 4
230000008350 antigen-specific antibody response Effects 0.000 claims 1
210000004027 cell Anatomy 0.000 description 63
108700002808 N-Me-Phe(3)- morphiceptin Proteins 0.000 description 39
238000003556 assay Methods 0.000 description 25
102000000588 Interleukin-2 Human genes 0.000 description 18
230000004913 activation Effects 0.000 description 14
210000004989 spleen cell Anatomy 0.000 description 13
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 12
235000001014 amino acid Nutrition 0.000 description 12
206010011968 Decreased immune responsiveness Diseases 0.000 description 9
238000001516 cell proliferation assay Methods 0.000 description 9
229960000367 inositol Drugs 0.000 description 9
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 9
230000000638 stimulation Effects 0.000 description 9
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 8
INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 8
229930105110 Cyclosporin A Natural products 0.000 description 7
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 7
108010036949 Cyclosporine Proteins 0.000 description 7
102000010789 Interleukin-2 Receptors Human genes 0.000 description 7
108010038453 Interleukin-2 Receptors Proteins 0.000 description 7
229960001265 ciclosporin Drugs 0.000 description 7
238000004166 bioassay Methods 0.000 description 6
229960004857 mitomycin Drugs 0.000 description 6
206010020751 Hypersensitivity Diseases 0.000 description 5
-1 Ser70 Proteins 0.000 description 5
230000006052 T cell proliferation Effects 0.000 description 5
230000000890 antigenic effect Effects 0.000 description 5
210000002950 fibroblast Anatomy 0.000 description 5
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 5
230000036961 partial effect Effects 0.000 description 5
230000009696 proliferative response Effects 0.000 description 5
235000018102 proteins Nutrition 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
229910019142 PO4 Inorganic materials 0.000 description 4
230000006044 T cell activation Effects 0.000 description 4
208000026935 allergic disease Diseases 0.000 description 4
230000007815 allergy Effects 0.000 description 4
230000000139 costimulatory effect Effects 0.000 description 4
230000016396 cytokine production Effects 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
230000006662 intracellular pathway Effects 0.000 description 4
230000037361 pathway Effects 0.000 description 4
235000021317 phosphate Nutrition 0.000 description 4
230000004044 response Effects 0.000 description 4
230000004936 stimulating effect Effects 0.000 description 4
238000012360 testing method Methods 0.000 description 4
239000012981 Hank's balanced salt solution Substances 0.000 description 3
101100341510 Mus musculus Itgal gene Proteins 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000006870 function Effects 0.000 description 3
108010068574 hemoglobin (64-76) Proteins 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
238000011282 treatment Methods 0.000 description 3
208000023275 Autoimmune disease Diseases 0.000 description 2
241000283707 Capra Species 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
108010054147 Hemoglobins Proteins 0.000 description 2
102000001554 Hemoglobins Human genes 0.000 description 2
102100022339 Integrin alpha-L Human genes 0.000 description 2
102000008070 Interferon-gamma Human genes 0.000 description 2
108010074328 Interferon-gamma Proteins 0.000 description 2
108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
102000008072 Lymphokines Human genes 0.000 description 2
108010074338 Lymphokines Proteins 0.000 description 2
241001529936 Murinae Species 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
230000005867 T cell response Effects 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
230000004940 costimulation Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000012997 ficoll-paque Substances 0.000 description 2
229940044627 gamma-interferon Drugs 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000004073 interleukin-2 production Effects 0.000 description 2
230000017290 interleukin-3 production Effects 0.000 description 2
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
230000007774 longterm Effects 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
230000002463 transducing effect Effects 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
PVQLRJRPUTXFFX-CIUDSAMLSA-N Ala-Met-Gln Chemical compound CSCC[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](CCC(N)=O)C(O)=O PVQLRJRPUTXFFX-CIUDSAMLSA-N 0.000 description 1
VJVQKGYHIZPSNS-FXQIFTODSA-N Ala-Ser-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N VJVQKGYHIZPSNS-FXQIFTODSA-N 0.000 description 1
WQKAQKZRDIZYNV-VZFHVOOUSA-N Ala-Ser-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WQKAQKZRDIZYNV-VZFHVOOUSA-N 0.000 description 1
KTXKIYXZQFWJKB-VZFHVOOUSA-N Ala-Thr-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O KTXKIYXZQFWJKB-VZFHVOOUSA-N 0.000 description 1
HCAUEJAQCXVQQM-ACZMJKKPSA-N Asn-Glu-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HCAUEJAQCXVQQM-ACZMJKKPSA-N 0.000 description 1
RATOMFTUDRYMKX-ACZMJKKPSA-N Asp-Glu-Cys Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)O)N RATOMFTUDRYMKX-ACZMJKKPSA-N 0.000 description 1
208000003950 B-cell lymphoma Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
ODBLJLZVLAWVMS-GUBZILKMSA-N Gln-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)N ODBLJLZVLAWVMS-GUBZILKMSA-N 0.000 description 1
FKJQNJCQTKUBCD-XPUUQOCRSA-N Gly-Ala-His Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)O FKJQNJCQTKUBCD-XPUUQOCRSA-N 0.000 description 1
HPCFRQWLTRDGHT-AJNGGQMLSA-N Ile-Leu-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O HPCFRQWLTRDGHT-AJNGGQMLSA-N 0.000 description 1
NZGTYCMLUGYMCV-XUXIUFHCSA-N Ile-Lys-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N NZGTYCMLUGYMCV-XUXIUFHCSA-N 0.000 description 1
DZMWFIRHFFVBHS-ZEWNOJEFSA-N Ile-Tyr-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)N DZMWFIRHFFVBHS-ZEWNOJEFSA-N 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
229940123618 Inositol 1 phosphatase inhibitor Drugs 0.000 description 1
102000000646 Interleukin-3 Human genes 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
102000004388 Interleukin-4 Human genes 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
YKIRNDPUWONXQN-GUBZILKMSA-N Lys-Asn-Gln Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N YKIRNDPUWONXQN-GUBZILKMSA-N 0.000 description 1
102000043131 MHC class II family Human genes 0.000 description 1
108091054438 MHC class II family Proteins 0.000 description 1
RBGLBUDVQVPTEG-DCAQKATOSA-N Met-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCSC)N RBGLBUDVQVPTEG-DCAQKATOSA-N 0.000 description 1
XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
SJRQWEDYTKYHHL-SLFFLAALSA-N Phe-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=CC=C3)N)C(=O)O SJRQWEDYTKYHHL-SLFFLAALSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
239000004280 Sodium formate Substances 0.000 description 1
PWPJLBWYRTVYQS-PMVMPFDFSA-N Trp-Phe-Leu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O PWPJLBWYRTVYQS-PMVMPFDFSA-N 0.000 description 1
102000014384 Type C Phospholipases Human genes 0.000 description 1
108010079194 Type C Phospholipases Proteins 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
108010081404 acein-2 Proteins 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
208000030961 allergic reaction Diseases 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
108010062796 arginyllysine Proteins 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
108010057085 cytokine receptors Proteins 0.000 description 1
102000003675 cytokine receptors Human genes 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
108010042598 glutamyl-aspartyl-glycine Proteins 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000004941 influx Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
238000005065 mining Methods 0.000 description 1
230000007896 negative regulation of T cell activation Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
108010084572 phenylalanyl-valine Proteins 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000009877 rendering Methods 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
235000019254 sodium formate Nutrition 0.000 description 1
239000000243 solution Substances 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
230000024664 tolerance induction Effects 0.000 description 1
230000003614 tolerogenic effect Effects 0.000 description 1
230000007306 turnover Effects 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
230000003827 upregulation Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Marine Sciences & Fisheries (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

CA002144409A 1992-09-11 1993-09-09 Peptides induisant une tolerance chez les cellules t et compositions a base de ces peptides Abandoned CA2144409A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US94379992A	1992-09-11	1992-09-11
US07/943,799		1992-09-11

Publications (1)

Publication Number	Publication Date
CA2144409A1 true CA2144409A1 (fr)	1994-03-31

Family

ID=25480282

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002144409A Abandoned CA2144409A1 (fr)	1992-09-11	1993-09-09	Peptides induisant une tolerance chez les cellules t et compositions a base de ces peptides

Country Status (6)

Country	Link
EP (1)	EP0666869A1 (fr)
JP (1)	JPH08503697A (fr)
AU (2)	AU4851893A (fr)
CA (1)	CA2144409A1 (fr)
NZ (1)	NZ256237A (fr)
WO (1)	WO1994006828A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6251396B1 (en)	1994-11-18	2001-06-26	Neurocrine Biosciences, Inc.	Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6379670B1 (en)	1994-11-18	2002-04-30	Neurocrine Biosciences, Inc.	Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US5874531A (en)	1995-03-07	1999-02-23	President And Fellows Of Harvard College	Identification of self and non-self antigens implicated autoimmune disease
US7084247B2 (en)	2004-03-11	2006-08-01	Peptimmune, Inc.	Identification of self and non-self antigens implicated in autoimmune diseases

1993
- 1993-09-09 CA CA002144409A patent/CA2144409A1/fr not_active Abandoned
- 1993-09-09 NZ NZ256237A patent/NZ256237A/en unknown
- 1993-09-09 WO PCT/US1993/008456 patent/WO1994006828A1/fr not_active Application Discontinuation
- 1993-09-09 EP EP93921426A patent/EP0666869A1/fr not_active Withdrawn
- 1993-09-09 AU AU48518/93A patent/AU4851893A/en not_active Abandoned
- 1993-09-09 JP JP6508150A patent/JPH08503697A/ja active Pending
1998
- 1998-02-16 AU AU53926/98A patent/AU5392698A/en not_active Abandoned

Also Published As

Publication number	Publication date
NZ256237A (en)	1997-05-26
EP0666869A1 (fr)	1995-08-16
AU4851893A (en)	1994-04-12
AU5392698A (en)	1998-04-09
WO1994006828A1 (fr)	1994-03-31
JPH08503697A (ja)	1996-04-23

Legal Events

Date	Code	Title	Description
2000-09-11	FZDE	Discontinued

Publication	Publication Date	Title
Gaur et al.	1997	Amelioration of relapsing experimental autoimmune encephalomyelitis with altered myelin basic protein peptides involves different cellular mechanisms
Markovic-Plese et al.	1995	T cell recognition of immunodominant and cryptic proteolipid protein epitopes in humans.
Teitelbaum et al.	2003	Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy
US6048529A (en)	2000-04-11	PVA or PEG conjugates of peptides for epitope-specific immunosuppression
CZ307202B6 (cs)	2018-03-21	Způsob in vitro pro identifikaci peptidů
Hashim et al.	1986	Biological activity of region 65–102 of the myelin basic protein
JPH075476B2 (ja)	1995-01-25	ホルモン活性を有する生物学的作用物質、その製法およびヒストンの医薬的用途
EP2254588B1 (fr)	2017-10-11	Procédés de préparation et composition de constructions de peptide utiles pour le traitement de la polyarthrite rhumatoïde
Blaser et al.	1998	Determinants and mechanisms of human immune responses to bee venom phospholipase A2
CA2203629A1 (fr)	1996-05-02	Compositions et traitement pour la sclerose en plaques
JP2607751B2 (ja)	1997-05-07	自己免疫性ブドウ膜網膜炎の治療予防薬
CA2248937C (fr)	2011-10-11	Agent immunotherapeutique a base peptidique pour le traitement des allergies
US7071297B2 (en)	2006-07-04	Tolerogenic peptides from myelin basic protein
Li et al.	1992	T cell epitope selection: dominance may be determined by both affinity for major histocompatibility complex and stoichiometry of epitope
CN105121463B (zh)	2020-11-27	肽
CZ329596A3 (en)	1997-05-14	Preparation for treating scattered sclerosis
CA2144409A1 (fr)	1994-03-31	Peptides induisant une tolerance chez les cellules t et compositions a base de ces peptides
Myers et al.	2007	PART III. Autoimmunity An Altered Peptide Ligand of Type II Collagen Suppresses Autoimmune Arthritis
JP2010235607A (ja)	2010-10-21	自己免疫疾患の診断薬と治療薬となるペプチド類
US20030190323A1 (en)	2003-10-09	Preparations and methods for the treatment of T cell mediated diseases
CZ298A3 (cs)	1998-06-17	Přípravky a způsoby ošetřování nemocí zprostředkovanými T buňkami
Rosloniec et al.	2006	Second-generation peptidomimetic inhibitors of antigen presentation effectively treat autoimmune diseases in HLA-DR-transgenic mouse models
CA3150887A1 (fr)	2021-03-25	Peptides pro-insuline pour le diabete de type 1
Sitaru et al.	2004	Allogeneic core amino acids of an immunodominant allopeptide are important for MHC binding and TCR recognition
JP4085105B2 (ja)	2008-05-14	アレルギー疾患に対するペプチド免疫療法剤